Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Aug 29:10:3015-3021.
doi: 10.2147/CMAR.S166468. eCollection 2018.

The predictive value of cumulative toxicity for quality of life in patients with metastatic colorectal cancer during first-line palliative chemotherapy

Claudia Sew Schuurhuizen  1   2 , Henk Mw Verheul  1 , Annemarie Mj Braamse  3 , Laurien M Buffart  1   2   3   4 , Haiko J Bloemendal  5 , Joost Dekker  2   6 , Inge Rhm Konings  1
Affiliations

The predictive value of cumulative toxicity for quality of life in patients with metastatic colorectal cancer during first-line palliative chemotherapy

Claudia Sew Schuurhuizen et al. Cancer Manag Res. .

Abstract

Background: Studies evaluating new systemic agents tend to report severe toxicities only, while the cumulative effect of multiple lower grade adverse events (AEs) may have an additional negative impact on patient quality of life (QOL). In the current observational cohort study, we evaluated whether, in patients with metastatic colorectal cancer receiving first-line chemotherapy, cumulative toxicity comprising all grades of AEs is more predictive for QOL than cumulative toxicity due to only high-grade AEs.

Methods: One hundred and five patients starting treatment completed the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30) questionnaire at baseline and 10 weeks. AEs, clinical outcomes, and demographics were retrieved from patient records. Cumulative toxicity scores were calculated in three ways: total number of high-grade AEs, total number of all-grade AEs, and total number of AEs multiplied by their grade (the severity score). Relations between cumulative toxicity scores and QOL were studied using multivariable linear regression analyses.

Results: The mean age of patients was 65 years, 68% were male, and 84% received oxaliplatin-based chemotherapy. A higher total number of AEs of all grades (B=-2.4, 95% CI=-3.9; -0.9) and the severity score (B=-1.4, 95% CI=-2.3; -0.5) were predictive for clinically relevant changes in physical QOL, whereas the total high-grade AEs was not. None of the cumulative toxicity scores were predictive for global QOL.

Conclusion: Cumulative toxicity scores comprising all grades of AEs provide a better measure of treatment burden than a toxicity score comprising high-grade AEs only. Physical QOL seems to be more affected by AEs than global QOL. Our results emphasize that future clinical trials should present cumulative toxicity scores comprising all AE grades as well as physical QOL instead of global QOL.

Keywords: adverse events; cumulative toxicity; metastatic colorectal cancer; quality of life; treatment-related toxicity.

PubMed Disclaimer

Conflict of interest statement

Disclosure JD and HV received a grant from the Alpe d’Huzes/Dutch Cancer Society (VU 2011-5279) during the conduction of the study. HV receives grants from Roche, Vitromics Healthcare System, Novartis, Immunovo B.V., Amgen, non-financial support from Pfizer, and honoraria from Boehringer Ingelheim. These resources were all received outside the submitted work. The authors report no other conflicts of interest in this work.

References

    1. Seruga B, Templeton AJ, Badillo FE, et al. Under-reporting of harm in clinical trials. Lancet Oncol. 2016;17(5):e209–e219. - PubMed
    1. National Cancer Institute . Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. US Department of Health and Human Services; 2009. [Accessed June 27, 2018]. Available from: www.hrc.govt.nz/sites/default/files/CTCAE%20manual%20-%20DMCC.pdf.
    1. Gilbert A, Ziegler L, Martland M, et al. Systematic review of radiation therapy toxicity reporting in randomized controlled trials of rectal cancer: a comparison of patient-reported outcomes and clinician toxicity reporting. Int J Radiat Oncol Biol Phys. 2015;92(3):555–567. - PubMed
    1. Castellanos EH, Chen SC, Drexler H, Horn L. Making the grade: the impact of low-grade toxicities on patient preference for treatment with novel agents. J Natl Compr Canc Netw. 2015;13(12):1490–1495. - PubMed
    1. Kalsi T, Babic-Illman G, Fields P, et al. The impact of low-grade toxicity in older people with cancer undergoing chemotherapy. Br J Cancer. 2014;111(12):2224–2228. - PMC - PubMed

LinkOut - more resources